<DOC>
	<DOCNO>NCT02363400</DOCNO>
	<brief_summary>Nasopharyngeal carcinoma ( NPC ) geographically endemic , Epstein-Barr virus ( EBV ) -associated carcinoma epidermoid origin . It occur commonly Southern China Southeast Asia . The NPC cell poorly differentiate undifferentiated high incidence lymphatic hematological dissemination . Because inherent anatomic constraint high degree radiosensitivity , radiotherapy ( RT ) primary treatment NPC patient . NPC also chemosensitive tumor . Various mode combine chemoradiotherapy use treat NPC patient advanced-stage disease recent 20 year . However , treatment outcome locoregionally advance NPC still unsatisfactory .</brief_summary>
	<brief_title>A Phase III Trial NPC With Post-radiation Detectable Plasma EBV DNA</brief_title>
	<detailed_description>The current NCCN guideline recommend CCRT + adjuvant chemotherapy advance ( stage III-IV ) NPC , originate result Intergroup study [ 69 ] . However , meta-analysis report benefit use adjuvant chemotherapy NPC patient [ 82-85 ] . These contradiction puzzle oncologist decade . In opinion , routine delivery post-radiation adjuvant chemotherapy RT±induction/concurrent chemotherapy `` '' advanced-stage NPC patient re-considered . The major goal adjuvant chemotherapy NPC reduce occurrence distant failure . But , advance NPC patient need adjuvant chemotherapy . In previous phase III study , 19.1 % ( 27/141 ) NPC patient 1988 AJCC stage III-IV disease develop distant failure CCRT . In another study 210 NPC patient 1997 AJCC stage IIB-IVB treat induction chemotherapy + RT , 55 patient ( 26.2 % ) suffer subsequent distant metastasis [ 67 ] . We remember unnecessary adjuvant therapy frequently use . For example , target patient high 50 % subsequent distant failure rate , adjuvant therapy protocol 50 % control rate subclinical disease . When treat target patient , 25 % patient benefit adjuvant therapy unnecessary treatment 50 % ineffective treatment another 25 % patient . Thus , adjuvant therapy design `` select '' patient . For NPC patient , pEBV DNA-guided adjuvant therapy trial reasonable . We plan prove adjuvant chemotherapy beneficial post-radiation detectable pEBV DNA patient prospective multi-center trial . We conduct another trial investigate ( compare ) adjuvant chemotherapy regimen best one future .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>1.Histological proven NPC . 2.2010 AJCC stage IIIVB . 3.Age ≧ 20 year old . 4.Performance status ECOG ≦ 2 . 5.Finished RT ≧ 66 Gy ( ± induction and/or concurrent chemotherapy ) . 6.pEBV DNA &gt; 0 copy/ml 1±1 week postRT . 7.Restaging workups 10±2 week postRT show active lesion . 8.Adequate liver , renal , bone marrow function 4 week randomization . 9.Signed informed consent . 1 . Pathologicallyproven presence locoregional disease and/or distant metastasis . 2 . Unequivocallyshown active NPC ( locoregional/distant ) image study . 3 . Inadequate RT . 4 . Received postRT adjuvant chemotherapy . 5. pEBV DNA = 0 copy/ml 1±1 week postRT . 6 . Previous delivery cisplatin dose &gt; 600 mg/m2 . 7 . Previous delivery epirubicin &gt; 360 mg/m2 . 8 . History malignancy except treated curative intent skin cancer ( melanoma ) , situ cervical cancer , ductal carcinoma situ ( DCIS ) breast . 9 . Severe cardiopulmonary disease ( unstable angina and/or congestive heart failure peripheral vascular disease require hospitalization within last 12 month ; chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization ) clinically significant psychiatric disorder . 10 . Female patient pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Nasopharyngeal carcinoma ( NPC )</keyword>
	<keyword>Epstein-Barr virus ( EBV )</keyword>
	<keyword>radiotherapy ( RT )</keyword>
	<keyword>Plasma EBV DNA ( pEBV DNA )</keyword>
	<keyword>Adjuvant Chemotherapy</keyword>
</DOC>